Pfizer begins pediatric trial of COVID-19 antiviral

Pfizer announced Wednesday that it has initiated a phase 2/3 study of its COVID-19 antiviral for pediatric patients.
Paxlovid, which contains tablets of the protease inhibitor nirmatrelvir and a low dose of ritonavir, is already available for patients aged 12 years or older under an emergency use authorization issued by the FDA in December.
The new pediatric trial is an open-label, multicenter, single-arm study that will enroll approximately 140 participants aged younger than 18 years.
Initial enrollment will include two cohorts of participants aged 6 to 17 years. The first will include children

Pfizer announced Wednesday that it has initiated a phase 2/3 study of its COVID-19 antiviral for pediatric patients.
Paxlovid, which contains tablets of the protease inhibitor nirmatrelvir and a low dose of ritonavir, is already available for patients aged 12 years or older under an emergency use authorization issued by the FDA in December.
The new pediatric trial is an open-label, multicenter, single-arm study that will enroll approximately 140 participants aged younger than 18 years.
Initial enrollment will include two cohorts of participants aged 6 to 17 years. The first will include children